The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) on Thursday reported a $161 million net loss in the third quarter, 67% wider than its $96.41 million loss a year earlier.

Looking up: Revenue for the quarter rose 33.5% to $57.54 million, benefiting from a 39% jump in revenue for its core oral oncology drug, Zejula, which generated $39.2 million.

Take Note: The company’s R&D expenses jumped 81% to $99.5 million during the period, equal to 173% of its total revenue. Selling, general and administrative expenses also rose 13% to $66.6 million, fueling the widening loss.

Digging Deeper: Zai Lab is a pharmaceutical company that licenses other companies’ drugs for the China market, with four main commercial therapies providing its revenues. However, the high cost of licensing has put the company in a difficult situation in recent years whereby the more revenue it generates, the greater its losses. To reverse the situation, the company started to shift its strategy to add more self-developed drugs by hiring R&D staff and initiating clinical trials to strengthen its independent R&D capability. However, this has also led to increased costs associated with clinical R&D, making it difficult to improve its losses in the near-term.

Market Reaction: After a 4.1% drop when markets opened on Thursday, Zai Lab shares rebounded during the morning and were down a more modest 1.1% at HK$22.70 by the midday break. They now trade at the lower end of their 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Sante makes infant nutritional products

Sainte Nutritional nurtures Hong Kong IPO

The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutritional has filed…
Illustration of the umbrella brand of Geely, which includes Zeekr, Volvo, Lotus.

Zeekr’s buyout stalls, and Chagee’s returns cool

A group of early investors in NEV maker Zeekr have protested a recent privatization bid for the company, saying it's too low. Will the buyer heed their complaints and raise its offer? And Chagee's maiden quarterly results show its revenue grew at just half the rate of its new store openings. What's behind the evaporting returns?